Literature DB >> 11561088

Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.

A Takeuchi1, S Masuda, H Saito, T Abe, K Inui.   

Abstract

We characterized the interactions of various compounds with OAT-K1 and OAT-K2, kidney-specific organic anion transporters. By using Madin-Darby canine kidney cells stably transfected with OAT-K1 or OAT-K2 cDNA, the antitumor drug methotrexate, the mycotoxin ochratoxin A, endogenous organic anions (thyroid hormones, taurocholic acid, and conjugated steroids), and the antiretroviral drug zidovudine were shown to be substrates for these transporters. Although the apparent Michaelis constant (Km) values of methotrexate for OAT-K1 and OAT-K2 were 2.1 and 1.8 microM, respectively, 2.5 mM methotrexate inhibited only 20% of the 125I-thyroid hormones uptake via these transporters. In addition, 100 microM methotrexate did not have any effect on [3H]zidovudine uptake via OAT-K1 or OAT-K2. Similarly, several substrates caused little or no mutual inhibition at concentrations much higher than their Km values for these transporters. Moreover, intracellular methotrexate trans-stimulated the OAT-K1- and OAT-K2-mediated uptake of [3H]folic acid, but not that of other compounds. Organic anion-transporting polypeptide 2 (oatp2), a liver-type homolog of OAT-K1 and OAT-K2, showed similar events. The inhibition constant values of triiodothyronine and taurocholic acid for [3H]digoxin uptake in oatp2-expressing oocytes resulted in 50.4 and 1.48 mM, respectively, which were about 9- and 40-fold higher than their Km values for oatp2, respectively. These findings suggested that several substrates interact with these transporters at different amino acid residue(s). Taken together, these observations suggested that OAT-K1 and OAT-K2 could serve as multispecific transporters, mediating transport of a wide variety of endogenous substances, xenobiotics, and their metabolites in the kidney, presumably via several interaction sites in their molecules.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561088

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Characterization of the mechanism of zidovudine uptake by rat conditionally immortalized syncytiotrophoblast cell line TR-TBT.

Authors:  Y Sai; T Nishimura; S Shimpo; T Chishu; K Sato; N Kose; T Terasaki; C Mukai; S Kitagaki; N Miyakoshi; Y-S Kang; E Nakashima
Journal:  Pharm Res       Date:  2008-03-12       Impact factor: 4.200

2.  Systemic gut microbial modulation of bile acid metabolism in host tissue compartments.

Authors:  Jonathan R Swann; Elizabeth J Want; Florian M Geier; Konstantina Spagou; Ian D Wilson; James E Sidaway; Jeremy K Nicholson; Elaine Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

Review 3.  Xenobiotic transporters and kidney injury.

Authors:  Blessy George; Dahea You; Melanie S Joy; Lauren M Aleksunes
Journal:  Adv Drug Deliv Rev       Date:  2017-01-20       Impact factor: 15.470

Review 4.  Minireview: thyroid hormone transporters: the knowns and the unknowns.

Authors:  W Edward Visser; Edith C H Friesema; Theo J Visser
Journal:  Mol Endocrinol       Date:  2010-07-21

5.  The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

Authors:  Omar Janneh; Andrew Owen; Patrick G Bray; David J Back; Munir Pirmohamed
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

6.  Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates.

Authors:  Adam L VanWert; Douglas H Sweet
Journal:  Pharm Res       Date:  2007-07-28       Impact factor: 4.200

7.  Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.

Authors:  Tsuyoshi Mikkaichi; Takehiro Suzuki; Tohru Onogawa; Masayuki Tanemoto; Hiroya Mizutamari; Masahiro Okada; Tatsuji Chaki; Satohiro Masuda; Taro Tokui; Nobuaki Eto; Michiaki Abe; Fumitoshi Satoh; Michiaki Unno; Takanori Hishinuma; Ken-Ichi Inui; Sadayoshi Ito; Junichi Goto; Takaaki Abe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

Review 8.  The SLCO (former SLC21) superfamily of transporters.

Authors:  Bruno Hagenbuch; Bruno Stieger
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

9.  Molecular mechanism of ochratoxin a transport in the kidney.

Authors:  Naohiko Anzai; Promsuk Jutabha; Hitoshi Endou
Journal:  Toxins (Basel)       Date:  2010-06-09       Impact factor: 4.546

Review 10.  Ochratoxin A: Molecular Interactions, Mechanisms of Toxicity and Prevention at the Molecular Level.

Authors:  Tamás Kőszegi; Miklós Poór
Journal:  Toxins (Basel)       Date:  2016-04-15       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.